Tenaya Therapeutics Inc (TNYA)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$0.39

-0.13 (-25.05%)

Market Cap: $116.82M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

67%(14/21)

Avg Surprise

-0.50%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.10

Range$-0.10 - $-0.09

4 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$-0.10+3.7%

60d ago$-0.10+3.7%

30d ago$-0.10+1.0%

7d ago$-0.10+1.0%

Current$-0.10

Revenue Consensus

$800000

Range$0 - $1M

4 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.17

Range$-0.24 - $-0.11

3 analysts

Revenue Consensus

$-14306000

Range$-17000000 - $-8100000

5 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.17	$-0.24 - $-0.11	-	-	3	-	-
Sep 30, 2026Sep 26EST	-	$-0.10	$-0.10 - $-0.09	-	-	4	0 3 30d	-
Jun 30, 2026Jun 26 Reported Aug 5, 2026Reported Aug 5	$-0.09	$-0.08	$-0.14 - $-0.04	-12.50%	Miss	6	1 0 30d	+35.7%
Mar 31, 2026Mar 26 Reported May 6, 2026Reported May 6	$-0.09	$-0.09	$-0.14 - $-0.05	+0.00%	Beat	6	1 0 30d	+62.5%
Dec 31, 2025Dec 25 Reported Mar 11, 2026Reported Mar 11	$-0.12	$-0.14	$-0.17 - $-0.10	+12.73%	Beat	8	4 0 30d	+57.1%
Sep 30, 2025Sep 25 Reported Nov 10, 2025Reported Nov 10	$-0.12	$-0.15	$-0.18 - $-0.10	+20.00%	Beat	8	5 0 30d	+60.0%
Jun 30, 2025Jun 25 Reported Aug 6, 2025Reported Aug 6	$-0.14	$-0.19	$-0.26 - $-0.11	+26.32%	Beat	8	1 3 30d	+58.8%
Mar 31, 2025Mar 25 Reported May 7, 2025Reported May 7	$-0.24	$-0.20	$-0.31 - $-0.14	-20.00%	Miss	6	3 0 30d	+40.0%
Dec 31, 2024Dec 24 Reported Mar 10, 2025Reported Mar 10	$-0.28	$-0.31	$-0.35 - $-0.28	+9.68%	Beat	8	1 0 30d	+30.0%
Sep 30, 2024Sep 24 Reported Nov 6, 2024Reported Nov 6	$-0.30	$-0.37	$-0.44 - $-0.33	+18.92%	Beat	8	No revisions (30d)	+23.1%
Jun 30, 2024Jun 24 Reported Aug 8, 2024Reported Aug 8	$-0.34	$-0.39	$-0.49 - $-0.28	+12.82%	Beat	9	No revisions (30d)	+24.4%
Mar 31, 2024Mar 24 Reported May 14, 2024Reported May 14	$-0.40	$-0.42	$-0.45 - $-0.40	+4.76%	Beat	7	No revisions (30d)	+7.0%
Dec 31, 2023Dec 23 Reported Mar 18, 2024Reported Mar 18	$-0.40	$-0.44	$-0.50 - $-0.40	+9.09%	Beat	8	No revisions (30d)	+34.4%
Sep 30, 2023Sep 23 Reported Nov 8, 2023Reported Nov 8	$-0.39	$-0.48	$-0.57 - $-0.40	+18.75%	Beat	7	No revisions (30d)	+47.3%
Jun 30, 2023Jun 23 Reported Aug 9, 2023Reported Aug 9	$-0.45	$-0.51	$-0.54 - $-0.46	+11.76%	Beat	6	No revisions (30d)	+34.8%
Mar 31, 2023Mar 23 Reported May 10, 2023Reported May 10	$-0.43	$-0.55	$-0.72 - $-0.45	+21.82%	Beat	6	No revisions (30d)	+42.7%
Dec 31, 2022Dec 22 Reported Mar 8, 2023Reported Mar 8	$-0.61	$-0.65	$-0.78 - $-0.51	+6.15%	Beat	6	No revisions (30d)	+3.2%
Sep 30, 2022Sep 22 Reported Nov 10, 2022Reported Nov 10	$-0.74	$-0.68	$-0.75 - $-0.55	-8.82%	Miss	6	No revisions (30d)	-8.8%
Jun 30, 2022Jun 22 Reported Aug 10, 2022Reported Aug 10	$-0.69	$-0.74	$-0.74 - $-0.74	+6.76%	Beat	0	No revisions (30d)	+94.8%
Mar 31, 2022Mar 22 Reported May 11, 2022Reported May 11	$-0.75	$-0.64	$-0.69 - $-0.57	-17.19%	Miss	4	No revisions (30d)	-87.5%
Dec 31, 2021Dec 21 Reported Mar 23, 2022Reported Mar 23	$-0.63	$-0.60	$-0.83 - $-0.40	-5.00%	Miss	4	No revisions (30d)	+94.7%
Sep 30, 2021Sep 21 Reported Nov 10, 2021Reported Nov 10	$-0.68	$-0.48	$-1.36 - $-0.36	-41.67%	Miss	4	1 1 30d	+93.3%
Jun 30, 2021Jun 21 Reported Jul 30, 2021Reported Jul 30	$-13.26	$-7.17	$-13.62 - $-0.73	-84.94%	Miss	2	No revisions (30d)	-
Mar 31, 2021Mar 21 Reported Jun 2, 2021Reported Jun 2	$-0.40	$0.00	-	N/A	Miss	-	-	-
Dec 31, 2020Dec 20 Reported Mar 31, 2021Reported Mar 31	$-11.93	$0.00	-	N/A	Miss	-	-	-
Dec 31, 2019Dec 19 Reported Mar 30, 2020Reported Mar 30	$-10.15	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-0.93	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	-1883.00%
ROE	-121.90%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	4.52x	Quick Ratio	4.52x
Trading Statistics
Beta	2.88	Avg Volume	3.84M
52-Week High	$2.02	52-Week Low	$0.36

Technical Indicators Dashboard

Moving Averages

SMA 10$0.54

SMA 20$0.59

SMA 50$0.66

SMA 200$0.73

EMA 10$0.53

EMA 20$0.57

EMA 50$0.64

EMA 200$0.75

MACD

Line: -0.05Signal: -0.04Hist: -0.01

ADX

ADX: 30.3+DI: 10.9-DI: 46.2

Aroon & PSAR

Aroon Up32.0

Aroon Down100.0

PSAR$0.57

Bollinger Bands

Upper Band$0.73

Lower Band$0.45

%B Position4711%(Upper)

Band Width-0.21

RSI (14-Day)

Oversold

19.9

Momentum Oscillators

Stoch %K13.3

Stoch %D19.3

Williams %R-89.1

ROC (10d)-35.3%

Momentum-0.21

CCI (20d)-224.6

MFI (14d)14.0

Volatility Measures

ATR (14d)$0.04(11.5%)

StdDev (20d)0.07

Hist Vol100.5%(High)

Volume Flow

VWAP$0.42

OBV-70.8M

AD Line-106.7M

CMF (20d)-0.431

Volume Metrics

Avg Vol (20d)4.0M

Vol Ratio4.5x(High)

VWMA (20d)$0.55

Pivot Points

R3$0.61

R2$0.59

R1$0.55

Pivot Point$0.54

S1$0.50

S2$0.48

S3$0.45

Advanced Oscillators

TSI-40.18

Ultimate Osc31.9

KST-196.59

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$1.11M	$225,000	$0	$0	$0	$0	$0	$0	$0	$0	$17.66M	$0
Cost of Revenue	$0	$0	$-3,948,000	$0	$0	$0	N/A	$0	$0	$0	$2.99M	$0
Gross Profit	$1.11M	$225,000	$3.95M	$0	$0	$0	N/A	$0	$0	$0	$-2,987,000	$0

Operating Expenses	$45.20M	$20.29M	$24.72M	$20.94M	$24.08M	$27.54M	$24.65M	$26.71M	$30.82M	$33.76M	$31.45M	$30.92M
R&D	$16.60M	$14.84M	$14.80M	$15.36M	$17.37M	$21.08M	$18.69M	$20.35M	$22.65M	$25.05M	$22.86M	$23.09M
SG&A	$5.41M	$5.45M	$5.98M	$5.57M	$6.71M	$6.46M	$5.96M	$6.36M	$8.17M	$8.71M	$8.58M	$7.83M
Operating Income	$-44,088,000	$-20,065,000	$-20,775,000	$-20,936,000	$-24,082,000	$-27,538,000	$-24,652,000	$-26,711,000	$-30,823,000	$-33,762,000	$-31,446,000	$-30,920,000

Interest Income	$697,000	$793,000	$575,000	$658,000	$815,000	$635,000	$812,000	$1.08M	$1.39M	$1.45M	$1.47M	$1.78M
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-43,393,000	$-19,272,000	$-20,175,000	$-20,275,000	$-23,283,000	$-26,864,000	$-23,836,000	$-25,634,000	$-29,431,000	$-32,228,000	$-29,935,000	$-29,143,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-43,393,000	$-19,272,000	$-20,175,000	$-20,275,000	$-23,283,000	$-26,864,000	$-23,836,000	$-25,634,000	$-29,431,000	$-32,228,000	$-29,935,000	$-29,143,000

EBITDA	$-42,392,000	$-18,302,000	$-18,348,000	$-18,958,000	$-21,745,000	$-24,807,000	$-22,799,000	$-24,625,000	$-28,559,000	$-31,599,000	$-27,538,000	$-29,053,000
EBIT	$-44,090,000	$-20,065,000	$-20,175,000	$-20,933,000	$-24,098,000	$-27,499,000	$-24,648,000	$-26,714,000	$-30,824,000	$-33,680,000	$-31,405,000	$-30,919,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about TNYA

News

Tenaya Therapeutics Inc. Research & Ratings | TNYA

This article provides an overview of Tenaya Therapeutics Inc. (TNYA), including its stock performance, market data...

Barron's•Oct 15, 2026 2:43 AM ET10/15/26•Somewhat-Bearish

Tenaya Therapeutics Inc. Advanced Charts | TNYA

This article provides advanced charting and financial data for Tenaya Therapeutics Inc. (TNYA), a biopharmaceutical company focused on cardiovascular diseases. It includes current stock performance metrics...

Barron's•Oct 14, 2026 9:14 AM ET10/14/26•Somewhat-Bearish

Tenaya Therapeutics (TNYA) Short Interest & Short Float | Updated Oct 2026

As of September 30, 2026, Tenaya Therapeutics (TNYA) reported a short interest of 22.92 million shares, representing 10.49% of its public float...

MarketBeat•Oct 9, 2026 4:40 PM ET10/9/26•Neutral

H.C. Wainwright Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3

H.C. Wainwright has reiterated its Buy rating for Tenaya Therapeutics (TNYA.US), maintaining a target price of $3. This indicates the firm's continued positive outlook on the company's stock performance and valuation.

Moomoo•Oct 7, 2026 2:31 AM ET10/7/26•Bullish

Tenaya Therapeutics, Inc. (TNYA) stock price, news, quote and history

Tenaya Therapeutics, Inc. (TNYA) stock information includes its current price, market data, and financial performance. The company, a clinical-stage biotechnology firm...

Yahoo Finance UK•Oct 3, 2026 2:57 AM ET10/3/26•Neutral

TNYA Valuation and Fair Value

P/E: -0.9x
P/B: 1.2x

See GNG's fair value

TNYA Profitability: Margins, ROIC and FCF

Operating margin: -1883.0%
Net margin: 0.0%
ROE: -121.9%

TNYA Competitors

Company	Ticker
LifeMD Inc	LFMD
Seer Inc	SEER
Fonar Corporation	FONR
Cassava Sciences Inc	SAVA
Nyxoah	NYXH
OUTLOOK THERAPEUTICS INC	OTLK
MaxCyte Inc	MXCT
Repare Therapeutics Inc	RPTX

Sector: Healthcare

TNYA Analyst Ratings

Consensus: Buy
Analysts: 7
Strong Buy: 2
Buy: 5
Hold: 0
Sell: 0
Strong Sell: 0

TNYA Bull Case vs Bear Case

Bull case

100.0% of TNYA's analyst ratings are Buy or Strong Buy.

TNYA Earnings: Beat Rate and Next Report

Beat rate: 5 of 8 quarters (62.5%)
Average surprise: 6.9%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.10
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 3 down

Frequently Asked Questions About TNYA

Does TNYA pay dividends?

Tenaya Therapeutics Inc (TNYA) does not currently pay a regular dividend.

What is TNYA's market cap?

Tenaya Therapeutics Inc (TNYA) has a market capitalization of $116.82M with a current stock price of $0.39.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In